Prolonged risk of subtrochanteric and diaphyseal femur fractures after discontinuing alendronate treatment: A nationwide nested case-control study in Taiwan  by Huang, Weng-Foung et al.
lable at ScienceDirect
Journal of Clinical Gerontology & Geriatrics 6 (2015) 54e58Contents lists avaiJournal of Clinical Gerontology & Geriatrics
journal homepage: www.e- jcgg.comOriginal articleProlonged risk of subtrochanteric and diaphyseal femur fractures after
discontinuing alendronate treatment: A nationwide nested
case-control study in Taiwan
Weng-Foung Huang, PhD a, b, Li-Chuang Chang, MS a, Yu-Hsiang Kao, MS a,
Yu-Wen Wen, PhD c, Fei-Yuan Hsiao, PhD d, e, f, Li-Ning Peng, MD b, g,
Yi-Wen Tsai, PhD a, b, **, Liang-Kung Chen, MD, PhD a, b, g, *
a Institute of Health Welfare and Policy, Taipei, Taiwan
b Aging and Health Research Center, National Yang Ming University, Taipei, Taiwan
c Clinical Informatics and Medical Statistics Research Center, College of Medicine, Chang Gung University, Taoyuan, Taiwan
d Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan
e School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan
f Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan
g Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwana r t i c l e i n f o
Article history:
Received 7 September 2014
Accepted 20 September 2014
Available online 27 November 2014
Keywords:
alendronate
bisphosphonate
osteoporosis
subtrochanteric femoral fracture* Corresponding author. Center for Geriatrics and
General Hospital, Number 201, Section 2, Shih-Pai Ro
** Corresponding author. Institute of Health Welfa
Ming University, Number 155, Section 2, Li-Nong Stre
E-mail addresses: ywtsai@ym.edu.tw (Y.-W. T
(L.-K. Chen).
http://dx.doi.org/10.1016/j.jcgg.2014.09.002
2210-8335/Copyright © 2014, Asia Paciﬁc League of Ca b s t r a c t
Background: The aim of this study is to evaluate the risk of subtrochanteric and diaphyseal femur fractures
and the persistence of this risk after discontinuation among elderly alendronate users in Taiwan.
Methods: This is a population-based, nested caseecontrol study collecting data from the Taiwan's
National Health Insurance. The study population consisted of patients aged 65 years or older who were
ﬁrst diagnosed with osteoporosis between 2001 and 2008. Cases of subtrochanteric femoral fractures
were deﬁned as such if these individuals were hospitalized with a primary diagnosis of subtrochanteric
or diaphyseal femur fractures during the study period. Based on risk-set control sampling, 10 matched
controls for each case by age, sex, cohort entry year, and the comorbidities of stroke, diabetes mellitus,
and osteoarthritis were obtained.
Results: A total of 2859 patients (mean age, 76.0 ± 6.7 years; 82% females) with subtrochanteric femoral
fractures were identiﬁed. Cases were more likely to use antiosteoporosis drugs, and they tend to use
alendronate longer (mean, 236 days vs. 215 days), with higher deﬁned daily dose (243.28 vs. 219.95) than
controls. Use of alendronate signiﬁcantly increased the risk for subtrochanteric femoral fractures: 0e3
years of follow-up [adjusted odds ratio (OR), 1.74; 95% conﬁdence interval (CI), 1.47e2.06], 3e5 years of
follow-up (adjusted OR, 1.74; 95% CI, 1.35e2.24), and >5 years of follow-up (adjusted OR, 1.50; 95% CI,
1.09e2.07). Use of alendronate for >1 year signiﬁcantly increased the risk of subtrochanteric femoral
fractures (adjusted OR, 1.64; 95% CI, 1.44e1.87); such association persisted longer than expected (3e5
years of follow-up: adjusted OR, 1.67; 95% CI, 1.27e2.19; >5 years: adjusted OR, 1.50; 95% CI, 1.07e2.11).
Conclusion: Discontinuation of alendronate therapy did not reduce the risk of subtrochanteric femoral
fractures until it was discontinued for >5 years. In conclusion, alendronate use signiﬁcantly increased the
risk of subtrochanteric femoral fractures, and the risk may persist for 5 years after discontinuation.
Copyright © 2014, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC.  Open access under CC BY-NC-ND license.Gerontology, Taipei Veterans
ad, Taipei, Taiwan.
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linical Gerontology & Geriatrics. P1. Introduction
Bisphosphonates (BPs) have been extensively used for the
treatment of osteoporosis and prevention of osteoporotic fractures
over the past 2 decades.1e4 Alendronate, the ﬁrst BP to be approved,
also signiﬁcantly increases bone mineral density and reduces the
risk of osteoporotic fractures.1,3e5 However, a case study published
in 2005 suggested a possible link between prolonged use of BPs andublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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the proximal femoral diaphysis); this report has drawn widespread
attention to BP use. Most of the previous cohort studies7e10 or post
hoc clinical trials11 reported no association between BP use and
atypical femoral fractures. However, results of those studies were
obtained without radiographic conﬁrmation of atypical femoral
fractures. One caseecontrol study, which included age- and sex-
matched participants, examined BP use in 63 patients who have
atypical femoral fractures with typical hip fractures. The study found
no signiﬁcant risks of atypical femoral fractures associated with BP
use.12 By contrast, another caseecontrol study showed a strong
association between BP use and atypical femoral fractures by
comparing the individual radiographs of 41 patients with atypical
femoral fractures with those of intertrochanteric fractures from 82
age-, sex-, and bodymass index-matched controls.6 The other recent
caseecontrol study of a large Canadian cohort of 205,466 women
aged 68 years or older, matched 716 cases with ﬁve controls and
reported a slight association between treatment with use of BPs for
>5 years and increased the risk of atypical femoral fractures.13 Lastly,
a recent population-based caseecontrol study has reported a
signiﬁcantly higher dose-dependent relationship between BP
exposure and atypical femoral fractures.14
To summarize the above-mentioned lines of evidence, most
caseecontrol studies with radiographic conﬁrmation that was not
universallyobservedby large-scaledatabase-basedstudies, supported
the connectionbetweenBPuseand subtrochanteric femoral fractures.
The inconsistent ﬁndings of these observational studies and case re-
ports have left clinicians and patients uncertain about the safety of
prescribingBPs.Moreover, becauseof the longhalf-life of alendronate,
the riskmaypersist longer than expected,which also deserves further
studies for clariﬁcation. Therefore, themainpurpose of this study is to
clarify the risk of subtrochanteric femoral fractures among BP users
and how long this risk persists after withdrawal of alendronate.
2. Materials and methods
2.1. Data source and study design
This is a population-based, nested caseecontrol study using the
Taiwan's National Health Insurance Research database, a nation-
wide database comprising anonymous enrollment information and
all insurance claims for visits, procedures, and medication pre-
scriptions for >99% of Taiwan's entire population (nearly 23
million). Inaugurated in 1996, Taiwan's National Health Insurance
(NHI) program is a mandatory social insurance program providing
Taiwan's residents with universal coverage for most medical care
services. For each outpatient visit or hospitalization, NHI collects
the date of visit, admission, and discharge on the patient's claims
record. Each claims record also contains up to ﬁve diagnoses coded
by physicians according to the International Classiﬁcation of Disease,
9th Edition (ICD-9 CM codes) and all medical service items, such as
medication, examinations, test, and rehabilitation, are claimed by
health care providers. Most of Taiwan's residents were enrolled in
1996 or at the time of their birth and remained insured for life. This
social health insurance program, therefore, maintains longitudinal
follow-up information for each person. The database, which has
been described in detail elsewhere,12 is routinely reviewed by the
Bureau of NHI of Taiwan to ensure its completeness and accuracy13
and has been the source for numerous epidemiological studies
published in peer-reviewed journals.
2.2. Study cohort
The study cohort consisted of patients aged 65 years or older
who were ﬁrst diagnosed to have osteoporosis between January 1,2001 and December 31, 2008. These patients might have received
any of the BPs, selective estrogen-receptor modulator (raloxifene),
hormone replacement therapy, calcitonin, or were not pharmaco-
logically treated. Cohort entry date was deﬁned as the date of ﬁrst-
time diagnosis of osteoporosis during the study period, based on
1-year washout criteria. Patients were excluded if they had been
hospitalized for any form of cancer 1 year prior to the entry date.
2.3. Cases with subtrochanteric femoral fractures and their controls
Cases of subtrochanteric femoral fractures in this osteoporotic
cohort were deﬁned as having subtrochanteric fractures if they had
been hospitalized at least once with a primary diagnosis of sub-
trochanteric fracture of the femur (ICD-9-CM code: 820.22 fracture
of subtrochanteric section of femur closed) or fracture of other and
unspeciﬁed parts of the femur (ICD-9-CM code: 821) during the
study period. The index date of incidencewas deﬁned as the date of
ﬁrst hospitalization for subtrochanteric femoral fractures during
the study period. Based on risk-set control sampling, we randomly
matched 10 controls for each subtrochanteric femoral fracture case
by age, sex, cohort entry year, and the comorbidities of stroke,
diabetes mellitus, and osteoarthritis. The controls were assigned an
index date for outcome observation identical to the date when the
matched case was ﬁrst hospitalized for subtrochanteric femoral
fractures during the study period.
2.4. Alendronate exposure
We examined the association between the use of alendronate
and the incidence of subtrochanteric femoral fractures. Use of
alendronate was analyzed in relation to the index date of sub-
trochanteric femoral fractures, and use of alendronate before sub-
trochanteric femoral fractures was categorized by the time from
last use (1month,1e6months, from6months to 1 year, or>1 year).
The total duration of alendronate usewas ﬁrst calculated as deﬁned
daily dose (DDD) prescribed during the cohort entry date and index
date of outcome and also the total medication days during the
observation period. The duration of each prescription was deter-
mined by the “days of supply” ﬁeld of the prescriptions shown on
the NHI claims records for each patient. Duration of usage was
calculated as cumulative days of total alendronate prescriptions
(<6 months, from 6 months to 1 year, and >1 year).
2.5. Statistical analyses
We ﬁrst explored the relationship between alendronate and
subtrochanteric femoral fractures by examining the association
between alendronate use and hospitalizations for subtrochanteric
femoral fractures. To explore the potential dose effect, we
compared patients with subtrochanteric femoral fractures who had
taken alendronate for <1 year with those who had taken it for >1
year. Among alendronate users, we also examined the potential risk
reduction after discontinuation of alendronate by classifying its use
according to the time since last use: 1 month, 1e6 months, from 6
months to 1 year, and >1 year. Because of the nature of matching in
caseecontrol studies, not every matched caseecontrol pair had
used alendronate for the same exact length of time. We repeated all
above-mentioned analyses on subpatient groups stratiﬁed by their
follow-up period (0e3 years, 3e5 years, and >5 years) instead of
prescription duration (Fig. 1).13
Because this study had a 1-to-10 matching design, we used
conditional logistic regressions to control the correlationwithin the
matched sample. Then, we estimated the odds ratios (ORs) and
95% conﬁdence intervals (CIs) for the association between use of
alendronate and subtrochanteric fractures among all patients and
Table 1
Characteristics in subtrochanteric fracture cases and matched controls (1:10).
n (%)
Cases (n ¼ 2859) Controls (n ¼ 28,590)
Age (y) 76.00 (6.66) 76.00 (6.66)
Sex
Men 525 (18.36) 5250 (18.36)
Women 2334 (81.64) 23,340 (81.64)
Disease before ﬁrst diagnosed as osteoporosis patient
Myocardial infarction 28 (0.98) 235 (0.82)
Stroke 89 (3.11) 890 (3.11)
Hypertension 771 (26.97) 8324 (29.12)
Hyperlipidemia 46 (1.61) 498 (1.74)
Diabetes mellitus 456 (15.59) 4560 (15.59)
Osteoarthritis 476 (16.65) 4760 (16.65)
Respiratory disease 254 (8.88) 2158 (7.55)
Dementia 66 (2.31) 502 (1.76)
Follow-up duration 986.2 ± 686.8 983.2 ± 684.5
Follow-up (grouped)
0e3 y 1740 (60.86) 17,515 (61.26)
3e5 y 692 (24.20) 6888 (24.09)
>5 y 427 (14.94) 4187 (14.65)
Alendronate
Not prescribed 2353 (82.30) 25,118 (87.86)
Prescribed 506 (17.70) 3472 (12.14)
Time since last use
Current (0e30 d) 128 (25.30) 750 (21.60)
Recent (31e180 d) 98 (19.37) 789 (22.72)
Past (180e365 d) 67 (13.24) 429 (12.36)
>365 d 213 (42.09) 1504 (43.32)
Duration of use
DDD 243.38 (355.60) 219.95 (307.45)
Raloxifene
Not prescribed 2673 (93.49) 27,285 (95.44)
Prescribed 186 (6.51) 1305 (4.56)
Duration of use
DDD 127.59 (174.59) 168.33 (223.42)
Calcitonin salmon
Not prescribed 2202 (77.02) 24,206 (84.67)
Prescribed 657 (22.98) 4384 (15.33)
Duration of use
DDD
Glucocorticoid
Not prescribed 1764 (61.70) 17,833 (62.37)
Prescribed 1095 (38.30) 10,757 (37.63)
Duration of use
DDD 16.88 (95.17) 15.16 (77.14)
Proton pump inhibitors
Not prescribed 2462 (86.11) 24,497 (85.68)
Prescribed 397 (13.89) 4093 (14.32)
Duration of use
DDD 27.93 (116.01) 17.52 (74.56)
Data are presented as mean ± SD or mean (SD).
DDD ¼ deﬁned daily dose; SD ¼ standard deviation.
Fig. 1. Deﬁnitions of exposure measurement.
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we adjusted the effect of use of raloxifene or calcitonin (during the
follow-up period; i.e., during the administration of alendronate and
after the discontinuation of alendronate) and use of glucocorticoids
and proton-pump inhibitors. For alendronate users, we applied a
similar analytical approach except that we included exposure to
alendronate (time used and time since last use). All analyses were
performed using R 2.13.1 (R citation: R Development Core Team
(2011), a language and environment for statistical computing;
R Foundation for Statistical Computing, Vienna, Austria; ISBN
3-900051-07-0, http://www.R-project.org/).
3. Results
3.1. Baseline characteristics
Over the 8-year study period, 2859 patients were admitted
because of subtrochanteric fractures of femurs. These cases were
age-, sex-, and diagnosis year-matchedwith 28,590 controls selected
from our study cohort; in addition, we used 10 controls for each case.
Table 1 shows a summary of the baseline characteristics of cases and
controls. The mean age was 76.0 [standard deviation (SD) ¼ 6.66]
years, and approximately 82% were women. Cases were also more
likely to have had a history of respiratory disease (8.88% vs. 7.55%)
and dementia (2.31% vs. 1.76%) when compared with their matched
controls. The mean follow-up duration for cases and controls were
986.2 days (SD ¼ 686.8) and 983.2 days (SD ¼ 684.5), respectively.
More than 60% were followed up for <3 years.
The cases were also more likely to be receiving treatment with
alendronate (17.70% vs. 12.14%), raloxifene (6.51% vs. 4.56%), or
calcitonin (22.98% vs. 15.33%) during the observation period. Among
alendronate users, cases were more likely to be current users than
controls (25.30% vs. 21.60%), with time since last use <30 days. Most
of the cases had stopped alendronate therapy for at least 1 year
(cases, 42.09%; controls, 43.32%). Cases who had used the drugs
longer than the controls (mean, 236 days vs. 215 days) had higher
DDDs (243.28 vs. 219.95). There was a higher proportion of cases
using raloxifene compared with controls (6.51% vs. 4.56%), whereas
among raloxifene users, cases had shorter duration of use (124 days
vs. 167 days) and had lower DDDs compared with controls (127.59
DDDs vs. 168.33 DDDs). The use of glucocorticoids (case: 38.30% vs.
control: 37.63%) and proton-pump inhibitors (case: 13.89% vs. con-
trol: 14.32%) were comparable among cases and controls.
3.2. Risk of subtrochanteric femoral fractures
An association between use of alendronate and increased risk of
hospitalization for subtrochanteric fractures of the femur was
found across the three subgroups: 0e3 years of follow-up (adjusted
OR, 1.74; 95% CI, 1.47e2.06), 3e5 years of follow-up (adjusted OR,1.74; 95% CI, 1.35e2.24), and >5 years of follow-up (adjusted OR,
1.50; 95% CI, 1.09e2.07). In order to examine the risk of sub-
trochanteric fractures of femurs among alendronate users, we
identiﬁed 506 cases and 3472 controls. Generally speaking, use of
alendronate for >1 year was associated with higher risk of sub-
trochanteric femoral fractures (adjusted OR, 1.64; 95% CI,
1.44e1.87); such association persisted when data were stratiﬁed by
length of follow-up: 3e5 years (adjusted OR, 1.67; 95% CI,
1.27e2.19) and >5 years (adjusted OR, 1.50; 95% CI, 1.07e2.11).
Furthermore, among all alendronate users, discontinuation of
alendronate therapy did not signiﬁcantly reduce the risk of sub-
trochanteric femoral fractures (Table 2).
4. Discussion
This nationwide nested caseecontrol study suggested that use
of BPs is weakly associated with subtrochanteric or femoral
Table 2
Conditional logistic regressions on the risk of subtrochanteric fractures among the elderly with diagnoses of osteoporosis.
Total number of patients Total Follow-up (0e3 y) Follow-up (3e5 y) Follow-up (>5 y)
No. of patients
Cases 2859 2859 1740 692 427
Controls 28,590 28,590 17,515 6888 4187
Cases Controls
Use alendronate Adjusted odds ratioa (95% CI)
Never 2353 (82.30) 25,118 (87.86) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Ever 506 (17.70) 3472 (12.14) 1.69 (1.50e1.92) 1.74 (1.47e2.06) 1.74 (1.35e2.24) 1.50 (1.09e2.07)
Alendronate users (n) 506 3472
Duration of use
Adjusted odds ratioa (95% CI)
&1 y 402 (79.45) 2856 (82.26) 1.00 (reference) 1.00 (reference)b 1.00 (reference) 1.00 (reference)
>1 y 104 (20.55) 616 (17.74) 1.64 (1.44e1.87) 1.72 (1.45e2.06) 1.67 (1.27e2.19) 1.50 (1.07e2.11)
Time since last use Adjusted odds ratioa (95% CI)
1 mo 128 (25.30) 750 (21.60) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
1e6 mo 98 (19.37) 789 (22.72) 0.82 (0.54e1.23) 0.84 (0.49e1.44) 0.89 (0.34e2.28) 0.48 (1.30e1.78)
From 6 mo to 1 y 67 (13.24) 429 (12.36) 0.97 (0.61e1.56) 0.81 (0.42e1.55) 0.80 (0.51e2.46) 1.79 (0.52e6.18)
>1 y 213 (42.09) 1504 (43.32) 0.74 (0.51e1.07) 0.64 (0.34e1.21) 0.82 (0.60e1.79) 0.65 (0.34e1.40)
a Adjusted by use of raloxifene or calcitonin (during the follow-up period; i.e., during the alendronate administration and after the discontinuation of alendronate) and use
of glucocorticoids and proton-pump inhibitors.
b Select those who were followed up for >1 year.
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to have osteoporosis during 2001 and 2008 (adjusted OR close to 1
and with narrow 95% CI). Among alendronate users, use of
alendronate for longer than 1 year was associated with sub-
trochanteric femoral fractures, but the risk of subtrochanteric
femoral fractures may be signiﬁcantly reduced when patients dis-
continued alendronate therapy for >1 year. Nevertheless, the risk of
subtrochanteric femoral fractures did not decrease rapidly after the
use of alendronate was discontinued, given the prolonged effect of
alendronate. Although the retrospective caseecontrol design of this
study cannot completely exclude the possibility of self-selection
effectdpatients with higher risk of fractures were more likely to
take BPs than those with lower riskdthe persistent risk of sub-
trochanteric femoral fractures found in this study deserves further
evaluation.
Results of this study suggested a very low risk of BP use on
subtrochanteric femoral fractures, which is consistent with the
conclusion of Giusti et al,12 but is inconsistent with most of the
other caseecontrol studies.6,13,14 However, owing to differences in
design of study between ours and others,6,13,14 including that of
Giusti et al,12 results from these caseecontrol studies should be
elaborated with caution. First, these caseecontrol studies all have
different study participants, in terms of study population and se-
lection criteria for control matching. Our study population was
more similar to that of Park-Wyllie et al,13 in that we started with a
cohort of patients with a diagnosis of osteoporosis aged 65 years
(68 years in Park-Wyllie et al's13 study). However, the main dif-
ferences are that we included male patients in our study, and the
participants were younger than those in the study of Park-Wyllie
et al13 (76 years vs. 83 years).13 Such differences may result from
the nationwide population-based study design of this research.
Another major difference between this study and others is the type
of statistical analysis used: unlike other statistical analyses that
were stratiﬁed by duration of BP use, our analysis was based on the
observational period. This analytic strategy allowed us to evaluate
the prolonged risk of subtrochanteric femoral fractures resulting
from BPs, which may last for about 5 years (as shown in this study).
Moreover, to adjust the self-selection effect, we analyzed the
association betweenduration of BP use and subtrochanteric femoral
fractures among alendronate users. However, because osteoporotic
patients in Taiwan tend to use BPs for a shorter period compared
with patients in other studies, we did not deﬁne long-term users inthe same way as other studies did (5 years). Instead, we catego-
rized their use into 1 year versus >1 year. Although our study
focuses on shorter duration of alendronate use, our ﬁndings are
consistent with those of other caseecontrol studies,6,13,14 but are
inconsistent with those of Giusti et al.12 However, we conclude this
result with caution. In general, the CIs of previous reports were
larger than ours owing to the limited number of subtrochanteric
femoral fracture cases. Moreover, the control group in this study
consisted of regular osteoporotic patients instead of patients with
typical hip fractures (as in other caseecontrol studies).
The key ﬁnding of this study is that the risk of subtrochanteric
femoral fractures among alendronate users was not reduced until
the patients ceased the treatment for >5 years. Schilcher et al14
reported that the risk of subtrochanteric femoral fractures
decreased rapidly after patients stopped the use of alendronate,
particularly in the 1st year. However, our study showed that the risk
of subtrochanteric femoral fractures may persist up to 5 years after
withdrawal. Since the half-life of alendronate to bone tissue may
last for 10 years,15 the persistent risk of subtrochanteric femoral
fractures in this study may not be surprising. The recommended
dose of alendronate for osteoporosis treatment was 70 mg regard-
less of ethnicity and body size, but this study may imply a more
persistent effect of alendronate in elderly Taiwanese. As such, this
issue deserves further pharmacokinetic studies for clariﬁcation.
Our study has several limitations. First, like most population-
based studies, we did not have the radiographic evidence to
verify the accuracy of deﬁning atypical femoral fractures. As
radiographic features that distinguish atypical femur fractures from
ordinary osteoporotic femoral diaphyseal fractures have been
highlighted in the latest task force report of the American Society
for Bone and Mineral Research,16 our case deﬁnition may result in
overestimation. Second, prescribed BPs may not be precisely equal
to the actual doses taken by patients in the claim data. Third, our
analyses focused on alendronate only. Nevertheless, there were
several reasons for doing this. First, alendronate was the most
frequently prescribed drug for osteoporosis in Taiwan. Second,
risedronate was not reimbursed and zolendronic acid was
restricted to cancer patients with hypercalcemia or bonemetastasis
under Taiwan's National Health Insurance system during our study
period.
However, our study does have its strengths. For instance, the
population-based claim data allowed us to obtainmore information
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rare incidence, a population-based database enables us to identify a
sufﬁcient amount of subtrochanteric femoral fractures, thereby
strengthening our statistical power. Although these subtrochanteric
femoral fractures in patients on BP therapy were rare, they have
raised increasing public and medical concerns because of its wide-
spread use and questions regarding long-term safety and optimal
duration of its use. This population-based nested caseecontrol
study, which is consistent with our previous cohort study, showed a
limited alendronate-related risk of subtrochanteric femoral frac-
tures. However, the risk increases once use of alendronate has
started andmay persist longer than ever expected. Thus, we suggest
that caution be exercised when alendronate is prescribed. Never-
theless, clinicians should always assess the risk/beneﬁt ratio of
alendronate for their patients as the beneﬁt of alendronate in
reducing risk of hip fractures4 has been well documented.Conﬂicts of interest
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